Pharmaceutical laboratories operating within or supplying the European market must fundamentally restructure their AI deployment strategies to comply with the European Union’s landmark EU AI Act. Distributors will also need to be acutely aware of the new requirements when the Act takes force.
The EU AI Act sets strict requirements for AI compliance, demanding new levels of accountability, documentation, and governance for AI systems. But the rules and the risks aren’t the same for all organisations.
- Providers must build compliance into AI system design
- Deployers must prove responsible oversight
- Distributers and importers of systems across the EU must ensure certain standards.
The challenge for drug developers is understanding EU AI Act compliance obligations while building processes that will scale with your business and adapt to future regulations.
As artificial intelligence moves from an experimental luxury to the backbone of modern drug discovery and laboratory automation, the regulatory landscape has tightened significantly. While pure basic research benefits from certain exemptions, any AI system that touches diagnostics, clinical software, or manufacturing faces stringent multi-layered oversight.
To maintain compliance and avoid severe financial penalties, pharmaceutical research and development (R&D) facilities must implement critical structural transformations across their workflows.
Indeed technology will need to comply with certain requirements including:
- Risk management issues
- Data quality
- Transparency
- Human oversight and accuracy.
While the businesses providing or deploying that technology will face obligations around registration, quality management, monitoring, record-keeping, and incident reporting.
Indeed, to maintain compliance and avoid severe financial penalties, pharmaceutical research and development (R&D) facilities must implement critical structural transformations across their workflows.
In order to facilitate the training, testing and development of the AI model, additional duties will fall on importers and distributors of high-risk AI systems, as well as the businesses that supply systems, tools, services, components, or processes that providers incorporate into their high-risk AI systems.
Establish clear risk segmentation in lab workflows
The EU AI Act governs technologies based on a strict tier of risk categories. Laboratories must audit their existing software tools and categorise them accurately:
- Research and early drug discovery (exempt): AI tools utilized strictly in early-stage research contexts – such as deep learning models predicting protein structures or identifying initial hit compounds – are generally exempt from the heaviest Act requirements.
- Regulated products & medical devices (high-risk): Software incorporating AI used to analyse patient samples, select candidates for clinical trials, or automate quality control in Good Manufacturing Practice (GMP) environments faces rigorous compliance deadlines. Under emerging guidelines, high-risk designations will require total adherence across regulated products.
Standardise AI data governance and data provenance
Pharmaceutical labs are historically built around Good Laboratory Practices (GLP), but AI introduces a data-integrity challenge that goes beyond traditional documentation.
- Bias and quality tracking: under the AI Act, high-risk systems require datasets to be free of toxic biases and fully traceable.
- Audit trails for models: labs must deploy rigorous version control for training algorithms. If an automated assay screening tool misidentifies a compound property, regulators will require a comprehensive data audit trail detailing the exact training weights, validation sets, and human-in-the-loop overrides used during deployment.
What is an AI system and when is it ‘high-risk’ under the EU AI Act?
According to Article 3(1) of the EU AI Act, an AI system is defined as: ‘a machine-based system that is designed to operate with varying levels of autonomy and that may exhibit adaptiveness after deployment, and that, for explicit or implicit objectives, infers, from the input it receives, how to generate outputs such as predictions, content, recommendations, or decisions that can influence physical or virtual environments.’
Unlike traditional software that follows strict, predetermined rule-based paths, an AI system must be capable of some level of independent deduction and learning, allowing it to evaluate data and make calculated outputs that impact its surrounding environment.
Under Article 6, an AI system is classified as high-risk if it meets either of the following two pathways:
Category 1: Safety Components of Regulated Products: an AI system is high-risk if it is intended to be used as a safety component of a product (or is itself a product) covered by EU harmonisation laws listed in Annex I (such as medical devices, aviation, cars, machinery, or toys) AND it is required to undergo a third-party conformity assessment before being placed on the market.
Category 2: Specific Critical Use Cases (Annex III): an AI system is also high-risk if it falls into one of the designated areas listed in Annex III due to its potential to negatively impact fundamental human rights or public safety.
An AI system is also high-risk if it falls into one of the designated areas listed in Annex III due to its potential to negatively impact fundamental human rights or public safety:
- Biometrics: Remote biometric identification, emotion recognition, or biometric categorisation systems.
- Critical infrastructure: Managing and operating networks like road traffic, water, or electricity grids where a failure could threaten lives.
- Education & Vocational Training: Systems determining admission, assigning students to institutions, or grading exams.
- Employment & HR: Recruitment software used to filter resumes, score candidates, or make promotion/termination decisions.
- Essential Private & Public Services: AI used to evaluate credit scores, determine loan eligibility, or assess eligibility for social welfare benefits and public aid.
- Law Enforcement: Predictive policing tools or systems evaluating evidence reliability.
- Migration, Asylum, & Border Control: Tools used to verify travel documents or predict security risks at border entry points.
- Administration of Justice & Democracy: AI systems assisting judges in legal research or tools used to influence outcomes in democratic elections.
Not all of this is directly relevant to the discovery, development and distribution of drugs, but a responsible AI manager must be aware.
Providers, deployers, importers and distributors of systems that meet that description need to consider whether those systems further qualify as ‘high-risk’ AI systems, according to the way the EU AI Act is drafted. There are three ways in which the legislation provides for AI systems to be considered ‘high-risk’:
- when the AI system is itself a certain type of product
- when the AI system is a safety component of a certain type of product
- when the AI system meets the description of listed ‘high-risk’ AI systems.
In pharma, an AI system can be a product itself. The EU AI Act recognises that AI systems may be an AI system and another form of product at the same time. Where those products are already subject to certain EU regulation, the EU AI Act provides for AI systems constituting such products to be considered ‘high-risk’ AI systems. For example, if an AI system constitutes medical devices of industrial machinery, it may be a product itself.
The Act recognises that AI systems can also be used as a safety component of a product. When that product is covered by the ‘Union harmonisation legislation’ and is required to undergo a third-party conformity assessment before it is placed on the market or put into service in the EU under that legislation, then the AI system safety component for that product will be automatically considered to be a ‘high-risk’ AI system.
From ‘black Box’ to explainable AI (XAI)
The traditional deep-learning paradigm – where an algorithm yields a prediction without explaining its rationale – is no longer viable for high-risk laboratory software. The EU framework mandates transparency.
- Scientists and lab technicians must be able to reasonably interpret AI-driven outputs
- Vendors providing automated laboratory hardware or laboratory information management systems (LIMS) must supply exhaustive documentation detailing their underlying algorithmic logic to allow laboratory operators to provide informed human oversight.
Continuous lifecycle monitoring and post-market auditing
Unlike static chemical compounds, AI models are dynamic entities susceptible to ‘data drift’ as laboratory instruments or baseline data change over time.
- Laboratories must implement continuous post-deployment monitoring protocols
- Standard Operating Procedures (SOPs) must be updated to include routine algorithmic validation cycles, ensuring that an automated system’s accuracy does not degrade over time, which could potentially compromise preclinical data or diagnostic results.
| Laboratory Domain | Core AI Use Case | EU AI Act Risk Tier | Primary Compliance Requirement |
| Early Discovery | De novo molecule generation, target identification | Exempt / Low Risk | Adherence to General Purpose AI (GPAI) codes of practice if using foundational models. |
| Clinical Trial Design | Patient stratification, predictive biomarkers | High-Risk | Technical documentation, extensive data governance, and logging obligations. |
| Lab Automation / Diagnostics | Automated GMP quality control, software as a medical device (SaMD) | High-Risk | Conformity assessments, strict human oversight, and post-market tracking. |
The path forward
Adapting to the EU AI Act requires immediate collaboration between data scientists, legal compliance teams, and laboratory directors. By embedding these risk assessment frameworks directly into digital transformation strategies, pharmaceutical organisations can continue leveraging AI’s immense efficiency gains without interrupting their pipeline to the global market. •
